• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 25
    • Directory
    • Microsites
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 25
  • Directory
  • Microsites
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    High Drug Loading Amorphous Solid Dispersions

    Parenteral Drug Delivery Trends

    Selecting the Right Outsourcing Model for Emerging Biotech

    Inhaled Drug Delivery Technology

    The Future of Biologics: Accelerating Production, Reducing Costs
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    Fusion Pharmaceuticals Acquires IPN-1087

    Strata Oncology Unveils Strata PATH Trial

    Alimentiv Acquires McDougall Scientific

    Q BioMed Inks Strontium89 Supply Pact

    PCI Pharma Services Appoints SVP, CFO
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    WuXi AppTec Completes OXGENE Acquisition

    Celonic Group Announces Plans for New Facility in Switzerland

    BMS Expands Cell Therapy Manufacturing Capabilities

    Novo Nordisk Invests $80M in Tablet Production

    Arcline Investment Acquires ChargePoint Technology
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    Reshaping the Pharmaceutical Supply Chain

    Covectra Introduces Next-Gen Serialization Solution

    Bormioli Opens New Glass Research Center

    Centrient Pharmaceuticals to Acquire Astral SteriTech

    Seasonal Vaccine Manufacturing
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    Strata Oncology Unveils Strata PATH Trial

    Alimentiv Acquires McDougall Scientific

    WuXi AppTec Completes OXGENE Acquisition

    Live Webinar - Formulation Strategies for Poorly Soluble Molecules

    Celonic Group Announces Plans for New Facility in Switzerland
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    Guide to Maintaining Validation of Older Facilities: Why, When and How

    The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021

    Top BioPharma Form Accumulus Synergy

    Global Biosciences Co. Selects ValGenesis VLMS

    Gene Therapy Co. Selects ValGenesis' SaaS Platform
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    Adare Pharma Solutions

    Cytovance Biologics

    Reed-Lane

    Alcami

    Emergent BioSolutions
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    Baxter BioPharma Solutions

    Alcami

    PCI Pharma Services

    Emergent BioSolutions

    Syngene
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
    • Contract Pharma Direct
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • Podcasts
    • White Papers
    • Infographics
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Conference Sessions
    • Supplier Microsite
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • eBook
    • Webinars
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Breaking News

    CPhI Report Addresses Battle Between Innovators and Biogenerics

    Regulation shifting due to increased data dependence, regulatory oversight is slowing six sigma, forecasts generic growth

    Related CONTENT
    • CPhI Worldwide Event Info
    • CPhI North America Event Info
    • Know the Challenges of Biosimilar Manufacturing
    • CPhI Report Evaluates Innovative Mfg. Processes
    • CPhI Report Highlights Anticipated CDMO Market Trends
    10.24.17
    CPhI Worldwide has released the findings of part III of its annual report  focused on the immediate and long-term trends in pharmaceutical data, regulation, generics and biosimilars. The report includes contributions from four experts in data, regulation, generics and biosimilars: Dilip G. Shah, Alan Sheppard, Bikash Chatterjee, and Ajaz S. Hussain.
     
    The overall findings warn that the FDA’s approach to achieving six sigma is currently failing, encouraging regulatory oversight, rather than the self-adoption of continuous quality systems by industry. A positive impact, however, was identified in the regulatory approach to data standards and analysis, which will see drug discovery and patient treatment advance over the next decade. For example, investments in handling big data will allow the industry to mine insight into historical performance and enable insight from e-clinical and post-market initiatives more effectively.
     
    The report also noted that the development of biogenerics is continuing to grow, and with the anticipated harmonization of biosimilar regulatory guidelines for both the U.S. and Europe, we should see an overall increase in players in the market, and the acceleration of generics and adoption. 
     
    Dilip G. Shah, chief executive officer of Vision Consulting Group, said the battle between innovators and biogeneric companies is likely to play out over the next three years, and that the tide is now gradually turning in favor of generic companies. Mr. Shah said, “The innovator companies will face increasing pressure to ensure access to medicines at affordable prices. But now the regulators and the governments will take on the innovators and force them to facilitate development of biogeneric versions over the next 2-3 years. The FDA Commissioner’s recent statement will encourage biogeneric companies to be more aggressive than they have been so far.  The FTC has already conveyed that it is contemplating launching a formal investigation. Thus, both drug regulator and the competition authorities will be on the same side.”
     
    Alan Sheppard, principal of Global Generics at IMS Health, suggests that there are still good opportunities for biosimilars in the industry. In the past, he claims, biosimilars were often viewed as a “risky venture” for pharmaceutical companies, but now could be the ideal time to invest.
     
    Mr. Sheppard said, “As with small chemical molecules there now exists biosimilar developers who are seeking partners for marketing and distribution and contract manufacturing organizations with biosimilar capabilities. If that is not an option then portfolio growth from small chemical molecules will still offer opportunities. The recent increase in launches of small chemical products forecasted to be potential blockbuster molecules will offer significant generic opportunities in the years beyond 2025.”
     
    Bikash Chatterjee, president and chief science officer of Pharmatech Associates, argues that the emergence of a global marketplace with shared regulatory compliance is one of many factors driving change in pharmaceutical regulation. A key element to this is the adoption of the PIC/S by 50 regulatory entities (with a further 70 expected to join by 2020). There have also been important legislation changes, for example the 21st Century Cures Act in late 2016 authorized new drug and device manufacturers to utilize real-life data to establish drug safety and efficacy for FDA approval.
     
    As a consequence of new high-throughput technology, notably next-gen sequencing, Mr. Chatterjee says that the role of data in illustrating performance and compliance will continue to increase over the next decade. Improvements in big data analytics will be crucial in highlighting the most suitable candidate drugs more quickly from e-clinical, lifestyle diagnostics and digital health initiatives. However, he highlighted cyber security as a potential risk factor, especially as the industry increases dependence on patient data for drug development. He added, “The industry’s ability to manage the constantly evolving threats to data management and integrity will define how we develop new drug therapies in the future.”
     
    Ajaz S. Hussain, Ph.D., founder of Insight, Advice & Solutions LLC, explores why a perpetual gap between what we know and what we can practice and implement – more than a decade after the launch of FDA’s 21st century initiative – remains. He explores how Amgen (as a case study) reached six sigma with an error rate of just 3.4 defects per million opportunities. Dr. Hussain stresses that much of the sector is held at a development stage – “socialized mind”. Systems orientation begins at the “self-authored” stage of development. The Amgen case illustrates how this can be achieved. However, in the synthetic drug product sector, the legacy practices – such as the use of compendial test methods for batch release testing – and the inherent uncertainty in measurement systems for physical attributes, such as dissolution tests, can serve as a “self-imposed” 2-3 sigma barrier. This barrier contributes to high OOS rates and high rates of invalidated OOS, which is a metric that the FDA is currently seeking from industry. Often this is not appreciated, and it serves as a blind spot.
    Related Searches
    • marketing
    • generics
    • study
    • Manufacturing
    Suggested For You
    CPhI Worldwide Event Info CPhI Worldwide Event Info
    CPhI North America Event Info CPhI North America Event Info
    Know the Challenges of Biosimilar Manufacturing Know the Challenges of Biosimilar Manufacturing
    CPhI Report Evaluates Innovative Mfg. Processes  CPhI Report Evaluates Innovative Mfg. Processes
    CPhI Report Highlights Anticipated CDMO Market Trends CPhI Report Highlights Anticipated CDMO Market Trends
    Frankfurt Hosts CPhI Worldwide 2017 Frankfurt Hosts CPhI Worldwide 2017
    Welcome to the 28th CPhI Worldwide! Welcome to the 28th CPhI Worldwide!
    CEO Spotlight:  Samsung Biologics CEO Spotlight: Samsung Biologics
    Sterile Manufacturing: Future Trends and Challenges Sterile Manufacturing: Future Trends and Challenges
    ABL Acquisition Extends Ardena’s Early-phase Offering ABL Acquisition Extends Ardena’s Early-phase Offering
    Contracting & Outsourcing Session Highlights and Key Takeaways Contracting & Outsourcing Session Highlights and Key Takeaways
    Ardena Launches following Pharmavize and Crystallics Merger Ardena Launches following Pharmavize and Crystallics Merger
    Know the Challenges of  Biosimilar Manufacturing Know the Challenges of Biosimilar Manufacturing
    Cancer Trials in the New Age of Drug Development Cancer Trials in the New Age of Drug Development
    Senate Passes FDA Reauthorization Act Senate Passes FDA Reauthorization Act

    Related Breaking News

    • Breaking News | Collaborations & Alliances | Drug Development | Industry News | Solid Dosage/Creams/Ointments
      Pfizer Partners with Medicines Manufacturing Innovation Center

      Pfizer Partners with Medicines Manufacturing Innovation Center

      To transform the formulation of oral solid dosage medicines.
      Tim Wright, Editor, Contract Pharma 02.25.21

    • Breaking News | Drug Development | Industry News
      Cyprium, Sentynl Therapeutics Ink Asset Purchase Agreement

      Cyprium, Sentynl Therapeutics Ink Asset Purchase Agreement

      Sentynl acquires CUTX-101 Copper Histidinate for the treatment of Menkes disease for $20 million in upfront and regulatory milestones.
      Kristin Brooks 02.24.21

    • Biologics, Proteins, Vaccines | Breaking News | Drug Development | Industry News | Information Technology
      Pfizer Selects Seven Bridges to Support RNA Sequencing Data

      Pfizer Selects Seven Bridges to Support RNA Sequencing Data

      Seven Bridges will centralize and manage terabytes scRNASeq data, which provides detailed analysis of gene expression in individual cells.
      Kristin Brooks 02.24.21


    • Breaking News | Drug Development | Promotions & Moves
      Aevitas Therapeutics Appoints President and CEO

      Aevitas Therapeutics Appoints President and CEO

      Dr. Markus Peters offers a 25-year track record of developing and commercializing orphan and specialty pharmaceuticals.
      Charles Sternberg, Assistant Editor 02.22.21

    • Breaking News | Collaborations & Alliances | Drug Development
      Lilly, Rigel Enter Exclusive CNS Development Collaboration

      Lilly, Rigel Enter Exclusive CNS Development Collaboration

      Lilly will pay $125 million upfront and up to $835 million in potential milestones for Rigel's lead RIPK1 inhibitor, R552.
      Kristin Brooks 02.18.21

    • Biologics, Proteins, Vaccines | Breaking News | Collaborations & Alliances | Drug Development
      Biomunex, Onward Ink Strategic Antibody Development Pact

      Biomunex, Onward Ink Strategic Antibody Development Pact

      Exclusive worldwide license and development agreement will leverage Biomunex' next gen bi- and multi-specific antibody platform in hematological malignancies.
      Kristin Brooks 02.16.21


    • APIs | Breaking News | Drug Development | Formulation Development | Industry News | Solid Dosage/Creams/Ointments
      Lonza Expands Solid Small Molecule Services

      Lonza Expands Solid Small Molecule Services

      To encompass all aspects of solid form screening and characterization of small molecule APIs.
      Kristin Brooks 02.16.21

    • Biologics, Proteins, Vaccines | Collaborations & Alliances | Drug Development
      Molecular Templates, BMS Enter Strategic Research Pact

      Molecular Templates, BMS Enter Strategic Research Pact

      Aims to discover and develop multiple therapies for specific oncology targets utilizing MTEM’s next-gen engineered toxin body (ETB) platform.
      Kristin Brooks 02.11.21

    • Bio News | Biologics, Proteins, Vaccines | Breaking News | Collaborations & Alliances | Drug Development | Industry News
      AbbVie, Caribou Ink CAR-T Collaboration

      AbbVie, Caribou Ink CAR-T Collaboration

      Leverages Caribou's next-generation CRISPR genome editing technology platform and AbbVie's antigen-specific binders.
      Tim Wright, Editor, Contract Pharma 02.10.21


    • Breaking News | Drug Development | Industry News | Laboratory Testing
      Quotient Sciences Acquires Arcinova

      Quotient Sciences Acquires Arcinova

      Acquisition expands Quotient’s services with drug substance, drug product and clinical testing capabilities.
      Kristin Brooks 02.09.21

    • Bio News | Biologics, Proteins, Vaccines | Breaking News | Drug Development | Industry News
      Paragon Biosciences Expands Cell and Gene Therapy Platform

      Paragon Biosciences Expands Cell and Gene Therapy Platform

      Launches CiRC Biosciences with an initial focus on developing eye disease treatments.
      Tim Wright, Editor, Contract Pharma 02.08.21

    • Biologics, Proteins, Vaccines | Breaking News | Drug Development | Trials & Filings
      J&J Submits EUA for Single-Shot Janssen COVID Vax Candidate

      J&J Submits EUA for Single-Shot Janssen COVID Vax Candidate

      Plans to distribute vaccine to U.S. government immediately following authorization, and expects to supply 100 million doses in 1H21.
      Kristin Brooks 02.05.21


    • Biologics, Proteins, Vaccines | Breaking News | Drug Development | Trials & Filings
      Vaxart Oral COVID-19 Vax Tablet Shows Promise

      Vaxart Oral COVID-19 Vax Tablet Shows Promise

      Phase I study reached primary and secondary endpoints of safety and immunogenicity.
      Kristin Brooks 02.03.21

    • Breaking News | Clinical Trials | Drug Development | Industry News
      Affimed, Roche Explore AFM24, Tecentriq Combo

      Affimed, Roche Explore AFM24, Tecentriq Combo

      To investigate the combination for the treatment of advanced solid epidermal growth factor receptor (EGFR) expressing malignancies.
      Kristin Brooks 02.03.21

    • Breaking News | Collaborations & Alliances | Drug Development
      Imcyse, Pfizer Enter Autoimmune Research Alliance

      Imcyse, Pfizer Enter Autoimmune Research Alliance

      Will develop Imotope candidates to potentially treat Rheumatoid Arthritis.
      Charles Sternberg, Assistant Editor 02.03.21

    Trending
    • BMS Expands Cell Therapy Manufacturing Capabilities
    • AbbVie Opts To Acquire Mitokinin
    • Bormioli Opens New Glass Research Center
    • Arcline Investment Acquires ChargePoint Technology
    • WuXi AppTec Completes OXGENE Acquisition
    Breaking News
    • Fusion Pharmaceuticals Acquires IPN-1087
    • Strata Oncology Unveils Strata PATH Trial
    • Alimentiv Acquires McDougall Scientific
    • Q BioMed Inks Strontium89 Supply Pact
    • PCI Pharma Services Appoints SVP, CFO
    View Breaking News >
    CURRENT ISSUE

    January/February 2021

    • High Drug Loading Amorphous Solid Dispersions
    • Parenteral Drug Delivery Trends
    • Selecting the Right Outsourcing Model for Emerging Biotech
    • Inhaled Drug Delivery Technology
    • The Future of Biologics: Accelerating Production, Reducing Costs
    • Business Intelligence For (and From) the Lab
    • Communicating Your Contracting Priorities to Your Drug Company Customers
    • COVID-19 Impact Report
    • The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    Low Levels of Vitamin D and Calcium Linked to COVID-19 Severity
    Probiotic Evidenced to Assist Digestive Recovery from a Complex Surgery
    AHPA Submits Comments to FDA on Proposed Traceability Rule
    Coatings World

    Latest Breaking News From Coatings World

    Chromaflo Technologies Adds Benjamin Woeste as Territory Sales Manager
    AOC Announces EMEA Price Increase
    Mule-Hide Products Co. Introduces Seal-Fast Liqui-Flash
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    NAMSA Acquires American Preclinical Services
    Quidel's QuickVue At-Home COVID-19 Test Earns EUA
    Memic Receives FDA Marketing Authorization for Hominis
    Contract Pharma

    Latest Breaking News From Contract Pharma

    Fusion Pharmaceuticals Acquires IPN-1087
    Strata Oncology Unveils Strata PATH Trial
    Alimentiv Acquires McDougall Scientific
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    IT Cosmetics Supports Women’s Confidence
    Inter Parfums Reports a Strong Fourth Quarter
    Universal Engraving Announces New President
    Happi

    Latest Breaking News From Happi

    Croda International Acquires Alban Muller
    Givaudan Active Beauty Launches Omegablue
    Sozio Acquires Scentessence
    Ink World

    Latest Breaking News From Ink World

    Massilly North America Adds Koenig & Bauer MetalStar 3 Metal Decorating Press
    Hydrocarbon Solvents Market to Surpass $8.1 Billion by 2030
    Access Direct Mail Doubles Revenue with SCREEN's Truepress Jet520HD
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    Abbott Label installs Domino K600i dual bar digital UV inkjet printer
    Crossmark turns to Eagle Systems for cold foil
    Maxcess launches Tidland PressureMax Airshaft Pressure Monitoring System
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    Domtar Completes Sale of Personal Care Business
    Mitsui to Sell Chinese Nonwovens Business
    Dr. J's Disinfectant Wipes Approved for Distribution in CA
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    FDA Approves Accufix Surgical's Accu-Joint Hemi Implant
    FDA OKs Q-Collar Device to Protect Athletes’ Brains During Head Impacts
    SeaSpine Releases Reef TO (TLIF Oblique) Interbody System
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    Comercial Kywi Improves Customer Service, Front-Store Operations with Zebra Mobile Solution
    Global Printed Circuit Board Market Projected to Reach $69.32 Billion by 2027
    Global Smart Glass Market to Register 6.8% CAGR Between 2021-28: Grand View Research

    Copyright © 2021 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login